ebastine (Kestin)

12/01/1989 - "It is concluded that ebastine (10-40 mg daily) is an effective and well tolerated treatment for hayfever."
03/01/2003 - "In conclusion, the comparative analysis of the results from these three trials shows that ebastine is efficacious in the reduction of nasal congestion associated with seasonal allergic rhinitis. "
10/01/2002 - "A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis."
01/01/1996 - "396 adult and adolescent patients with seasonal allergic rhinitis participated in this randomised double-blind parallel-group study in which the efficacy and tolerability of ebastine 10 or 20mg administered once daily in the morning or evening for 3 weeks were compared with those of placebo. "
01/01/1996 - "Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US."

12/01/2008 - "In addition, ebastine was significantly more effective than placebo at relieving the symptoms of chronic idiopathic urticaria. "
01/01/2022 - "To assess the efficacy and safety of escalated doses of ebastine in patients with chronic urticaria (CU), we designed this study. "
01/01/2022 - "Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study."
09/01/2011 - "Ebastine in chronic spontaneous urticaria in higher doses."
01/01/1996 - "Thus, these results, which show ebastine to be an effective and well tolerated agent, indicated that the drug should be considered for the first-line therapy of chronic urticaria."

12/01/1991 - "Ebastine treatment produced a significant reduction in the incidence and severity of most symptoms associated with perennial rhinitis. "
10/01/2002 - "Following 2 weeks' treatment, no significant differences (p > or = 0.91) were found between the ebastine with and without food groups in the percentage change from baseline of daily "reflective" total rhinitis symptom scores (i.e., patients' assessment of severity over the previous 12 h), but both ebastine groups exhibited significantly greater reductions versus patients receiving placebo (p < 0.0001). "
08/01/2008 - "Patients with rhinitis rate ebastine FDT very highly in terms of its formulation, convenience of use and its rapid onset of action. "
10/01/1996 - "[Ebastine : treatment of perennial rhinitis in the child]."
01/01/1996 - "In conclusion, ebastine 10mg once daily in the morning is an appropriate starting dose for the treatment of rhinitis, and this can be increased to 20mg as required."

03/01/2003 - "Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis."
01/01/2009 - "The aim of this study is to preliminarily evaluate IFN-gamma production by peripheral blood mononuclear cells (PBMNC) and clinical changes after a treatment with lyophilized ebastine in patients with persistent allergic rhinitis (PER). "
04/01/1993 - "In a double-blind, parallel-group study of a single 5 mg or 10 mg dose of ebastine syrup used to treat allergic rhinitis in 20 children aged 6 to 12 years, we tested the hypothesis that the medication would have a duration of action of at least 24 hours. "
08/23/2021 - "The main objective of this research work was the development and evaluation of transfersomes integrated oral films for the bioavailability enhancement of Ebastine (EBT) to treat allergic rhinitis. "
10/14/2010 - "Clinical utility and patient adherence with ebastine for allergic rhinitis."

06/01/1999 - "This double-blind, placebo-controlled, multicentre study investigated the ability of ebastine, 10 and 20 mg once daily, to control symptoms of perennial allergic rhinitis (PAR) over a 12-week period, and assessed additional benefits of the 20-mg dose. "
06/01/1999 - "A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. "
12/01/1991 - "Oral ebastine, 10 mg once daily for seven days, and placebo were compared as treatment for active perennial allergic rhinitis in 151 patients in a multicenter, randomized, double-blind trial. "
12/01/1991 - "Ebastine in perennial allergic rhinitis."
12/01/2008 - "Ebastine is a second-generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis. "